Oncology Development Strategies: Considerable Commercial Potential but Specific Needs Must be Addressed
- Language: English
- Published: January 2013
- Region: Global
The analysts forecast the Global Epinephrine Auto-injector market to grow at a CAGR of 13.34 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing prevalence of allergies. The Global Epinephrine Auto-injector market has also been witnessing the development of chlorofluorocarbon-free epinephrine auto-injector inhalers. However, the adverse side-effects of epinephrine drugs could pose a challenge to the growth of this market.
The report, the Global Epinephrine Auto-injector Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market in the Americas and the EMEA and APAC regions; it also covers the Global Epinephrine Auto-injector market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
The key vendors dominating this space include ALK Abello A/S, Amedra Pharmaceuticals LLC, Lincoln Medical Ltd., Mylan Inc., and Sanofi SA.
The other vendors mentioned in the report are Adamis Pharmaceuticals Corp., Antares Pharma Inc., Hospira Inc., Intelliject Inc., and Teva Pharmaceuticals Industries Ltd.
Key questions answered in this report:
- What will the market size be in 2016 and what will be the growth rate?
- What are key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by key vendors?
- What are the strengths and weaknesses of each of these key vendors?
You can request one free hour of our analyst's time when you purchase this market report. Details provided within the report.
The report is also available as part of our annual subscription offer. Please get in touch with our customer service team in order to find out more. SHOW LESS READ MORE >
01. Executive Summary
02. List of Abbreviations
04. Market Research Methodology
Market Research Process
05. Scope of the Report
06. Market Landscape
06.1 Global Epinephrine Auto-Injector Market
Market Size and Forecast
06.2 Epinephrine Auto-Injector Market in the US
Market Size and Forecast
06.3 Five Forces Analysis
07. Geographical Segmentation
08. Key Leading Countries
09. Rate of Incidence and Prevalence
10. Vendor Landscape
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Key Vendor Analysis
17.1 ALK Abello A/S
17.2 Amedra Pharmaceuticals LLC
17.3 Lincoln Medical Ltd.
17.4 Mylan Inc.
17.5 Sanofi SA
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Epinephrine Auto-Injector Market 2012-2016 (US$ million)
Exhibit 3: Epinephrine Auto-Injector Market in the US 2012-2016 (US$ million)
Exhibit 4: Global Epinephrine Auto-Injector Market by Geographical Segmentation 2012
Exhibit 5: Business Segmentation of ALK Abello A/S
Exhibit 6: Business Segmentation of Mylan Inc.
Exhibit 7: Business Segmentation of Sanofi SA
Commenting on the report, an analyst from the team said: “The inhalers used for the treatment of asthma patients in the past combined a mixture of epinephrine powder and CFC as an aerosol. However, the government in the US imposed a ban on the use of CFC as a propellant in inhalers. Primatene Mist, the only FDA-approved over-the-counter epinephrine inhaler containing CFC, was pulled by the FDA on December 31, 2011. Primatene Mist was the only FDA-approved epinephrine inhaler available in the market for the temporary relief of occasional symptoms of mild asthma. Hence, vendors are increasing their investment in R&D to develop a CFC-free epinephrine inhaler using hydrofluoroalkane as a propellant.”
According to the report, though epinephrine is produced in the body, chemically synthesized epinephrine drugs are used in the treatment of anaphylactic shock that occurs in people who are suffering from allergy, cardiac arrest, and asthma. The increase in the number of people who are allergic to food, food additives, dust, and insect venom has led to an increase in the use of epinephrine drugs. This is one of the major factors that drive the growth of the Global Epinephrine Auto-injector market.
Further, the report states that one of the main challenges in the market is that epinephrine drugs can cause adverse side effects such as vomiting, cardiac arrhythmia, hyperuricemia, lactic acidosis, pulmonary edema, and cerebral hemorrhage. Hence, physicians prefer to prescribe immunotherapy and other alternative pharmacotherapy drugs for the treatment of allergies.
The report also includes a discussion of the other vendors operating in this market. The other vendors in the market are Adamis Pharmaceuticals Corp., Antares Pharma Inc., Hospira Inc., Intelliject Inc., and Teva Pharmaceutical Industries Ltd.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
- Adamis Pharmaceuticals Corp.
- ALK Abello A/S
- Amedra Pharmaceuticals LLC
- Antares Pharma Inc.
- Hospira Inc.
- Intelliject Inc.
- Lincoln Medical Ltd.
- Mylan Inc.
- Sanofi SA.
- Teva Pharmaceuticals Industries Ltd.